Agent Orange Linked to Skin Cancer Risk, Reports Plastic and Reconstructive Surgery

Decades Later, High Rates of Non-Melanoma Invasive Skin Cancer in Exposed Vietnam Veterans

Released: 28-Jan-2014 2:00 PM EST
Source Newsroom: Wolters Kluwer Health: Lippincott Williams and Wilkins
Contact Information

Available for logged-in reporters only

Citations Plastic and Reconstructive Surgery

Newswise — Philadelphia, Pa. (January 28, 2014) –Vietnam War veterans with prior exposure to the herbicide Agent Orange may be at higher risk for certain types of skin cancer, suggests a report in the February issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS).

The study adds to previous evidence that risk of non-melanotic invasive skin cancer (NMISC) is increased even four decades after Agent Orange exposure, with at least some exposed veterans having unusually aggressive non-melanoma skin cancers. The lead author was ASPS Member Surgeon Dr. Mark W. Clemens of The University of Texas MD Anderson Cancer Center and colleagues.

Skin Cancers Present in About Half of Vets Exposed to Agent Orange
During the Vietnam War, Agent Orange was widely used as herbicide and jungle defoliant. It has been linked to a wide range of cancers and other diseases, caused by the highly toxic dioxin contaminant TCDD. "TCDD is among the most carcinogenic compounds ever to undergo widespread use in the environment," according to Dr. Clemens and coauthors. Veterans Affairs recognizes and provides benefits for certain cancers and health problems associated with prior dioxin exposure during military service, however skin cancer is currently not one of them.

The researchers analyzed medical records of 100 consecutive men who enrolled in the Agent Orange registry at the Veterans Affairs Hospital of Washington, DC, between August 2009 and January 2010. Exposure to TCDD consisted of living or working in contaminated areas for 56 percent of veterans, actively spraying Agent Orange in 30 percent, and traveling in contaminated areas for 14 percent. The study was limited to men with lighter skin types.

The rate of NMISC in TCDD-exposed veterans was 51 percent—about twice as high as the rate expected in men of similar age group. The risk of skin cancer increased to 73 percent for veterans who actively sprayed Agent Orange. Exposed men with the lightest skin types and those with lighter eyes were also at higher risk.

Forty-three percent of the veterans had chloracne, a skin condition specifically caused by exposure to dioxins. For this group, the rate of NMISC was more than 80 percent.

Call for More Research on Risks and Treatment
The rate of malignant melanoma, the most serious type of skin cancer, was similar to that expected in men of similar age. However, the article includes two case reports of unusually aggressive NMISC—with numerous recurrences requiring multiple surgeries—occurring in TCDD-exposed veterans.

Exposure to Agent Orange and TCDD has been linked to a wide range of health problems, including many different cancers. However, its association with the basal cell carcinoma and squamous cell carcinoma—the two most common types of skin cancer—has been unclear.

Cases of "aggressive and diffuse" non-melanoma skin cancers in TCDD-exposed veterans were first reported in plastic surgery journals in the mid-1980s. Dr. Clemens and colleagues initiated their study after observing similar patients in their clinic over the last few years. The researchers emphasize that their study has some important limitations—including the lack of detailed information on TCDD exposure and the absence of a comparison group of Vietnam-era veterans not exposed to Agent Orange.

Nevertheless, the results strengthen the previously reported association between TCDD exposure and the development of NMISC, even many years after exposure. Certain groups appear to be at particularly high risk, including veterans actively involved in spraying Agent Orange, those with chloracne, and those with lighter skin types. Dr. Clemens and coauthors write, "Further studies are warranted to determine the relative risk within this patient population and to determine appropriate management strategies so that veterans may receive the care they earned in service."

Plastic and Reconstructive Surgery® is published by Lippincott Williams & Wilkins, part of Wolters Kluwer Health.

# # #

About Plastic and Reconstructive Surgery
For more than 60 years, Plastic and Reconstructive Surgery® (http://journals.lww.com/plasreconsurg/) has been the one consistently excellent reference for every specialist who uses plastic surgery techniques or works in conjunction with a plastic surgeon. The official journal of the American Society of Plastic Surgeons, Plastic and Reconstructive Surgery® brings subscribers up-to-the-minute reports on the latest techniques and follow-up for all areas of plastic and reconstructive surgery, including breast reconstruction, experimental studies, maxillofacial reconstruction, hand and microsurgery, burn repair, and cosmetic surgery, as well as news on medico-legal issues.

About ASPS
The American Society of Plastic Surgeons (ASPS) is the world's largest organization of board-certified plastic surgeons. Representing more than 7,000 Member Surgeons, the Society is recognized as a leading authority and information source on aesthetic and reconstructive plastic surgery. ASPS comprises more than 94 percent of all board-certified plastic surgeons in the United States. Founded in 1931, the Society represents physicians certified by The American Board of Plastic Surgery or The Royal College of Physicians and Surgeons of Canada. ASPS advances quality care to plastic surgery patients by encouraging high standards of training, ethics, physician practice and research in plastic surgery. You can learn more and visit the American Society of Plastic Surgeons at www.plasticsurgery.org or www.facebook.com/PlasticSurgeryASPS and www.twitter.com/ASPS_news.

About Wolters Kluwer Health
Wolters Kluwer Health is a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Serving more than 150 countries and territories worldwide, Wolters Kluwer Health’s customers include professionals, institutions and students in medicine, nursing, allied health and pharmacy. Major brands include Health Language®, Lexicomp®, Lippincott Williams & Wilkins, Medicom®, Medknow, Ovid®, Pharmacy OneSource®, ProVation® Medical and UpToDate®.

Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company. Wolters Kluwer had 2012 annual revenues of €3.6 billion ($4.6 billion), employs approximately 19,000 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America. Follow our official Twitter handle: @WKHealth.


Comment/Share